Wockhardt Q3 FY27 profit drops 11% as Zaynich launch costs bite

⚡ Key Financial Takeaways

Net profit fell 11% YoY to Rs 73 crore in Q3 FY27, driven by Rs 36 crore of pre‑launch spend on Zaynich.

Revenue jumped 24% YoY to Rs 969 crore, but EBITDA margin slipped to 17% from 20.5% as launch costs were absorbed.

Adjusted EBITDA, excluding Zaynich expenses, would have risen 26% YoY to Rs 201 crore, showing underlying profitability.

Biotechnology revenue surged 68% YoY to Rs 252 crore, becoming a key growth engine for the company.

Zaynich received FDA approval (May 2026) and Indian CD SCO approval (Aug 2026); EMA review is ongoing, but commercial revenue timelines remain undisclosed.

💡 Why It Matters

The quarter highlights the trade‑off between short‑term earnings pressure and long‑term strategic positioning. While launch expenses for Zaynich depress margins now, successful commercialization could give Wockhardt a differentiated antibiotic in a market with few new entrants, potentially strengthening its global footprint and offsetting pricing pressures in other segments.

Profit dip masked by strong revenue growth Wockhardt’s consolidated net profit for the September quarter of FY27 slipped to Rs 73 crore, an 11% decline from the same period a year earlier. The fall contrasts with a 24% rise in revenue to Rs 969 crore, reflecting robust demand across its pharmaceutical and biotechnology portfolios.

Launch spending on Zaynich erodes margins The company recorded Rs 36 crore of pre‑launch expenses linked to its novel antibiotic Zaynich. These costs pushed the EBITDA margin down 350 basis points to 17% and limited operating profit growth to just 3% YoY (Rs 165 crore). When stripped of the launch spend, EBITDA would have been Rs 201 crore, a 26% increase year‑on‑year, and the adjusted operating margin would have stood at 20.8%.

Sequential performance shows mixed signals Quarter‑on‑quarter, revenue rose from Rs 929 crore in Q2 to Rs 969 crore, yet EBITDA fell from Rs 188 crore to Rs 165 crore and net profit dropped from Rs 107 crore to Rs 73 crore, underscoring the short‑term impact of the Zaynich rollout.

Regulatory milestones for Zaynich and pipeline updates - U.S. FDA approval (May 29 2026) for complicated urinary tract infections, including pyelonephritis. - India’s CD SCO approval (Aug 25 2026) for the same indications. - European Medicines Agency is reviewing the dossier, covering a broader set of infections.

Wockhardt has not disclosed expected sales from Zaynich or a timeline for recouping the launch outlay.

Other antibiotics and biotech growth - Emrok and Emrok O posted 40% Q3 growth, continuing a 37% rise in the first half of FY27. - Miqnaf received regulatory relief in India, expanding its patient reach. - Foviscu, a cefiderocol‑like candidate, completed Phase 2/3 trials and a new drug application has been filed. - The biotechnology segment surged 68% YoY to Rs 252 crore, driven by insulin products and expanding presence in emerging markets such as Brazil, Thailand, Egypt and Algeria.

Half‑year highlights For the six months ended September 2026, consolidated revenue climbed 25% to Rs 1,898 crore, EBITDA rose 35% to Rs 353 crore and the operating margin improved to 18.6%. Net profit turned positive at Rs 180 crore, reversing a loss of Rs 26 crore a year earlier. Excluding Rs 45 crore of Zaynich pre‑launch costs, H1 EBITDA would have been Rs 398 crore.

Intellectual property and international expansion The quarter saw 24 international product filings, 18 approvals, 11 launches, plus biosimilar filings and approvals. Patent activity added seven new filings and six grants, taking cumulative filings to 3,298 and patents held to 865.

Outlook Wockhardt aims to file for an additional indication for Zaynich covering upper respiratory tract infections in Q3 or Q4 FY27. The company’s ability to translate its expanding biotech revenue and pipeline progress into sustainable profitability will be closely watched.

---

🏛️ Background & Context

Wockhardt has been rebuilding its pipeline after a period of stagnation, focusing on novel antibiotics and biotechnology products. The approval of Zaynich in the U.S. and India marks a rare success for an Indian‑origin antibiotic, a sector where few new drugs have reached market in recent years. The company's biotech arm, driven by insulin and emerging‑market demand, is becoming an increasingly important revenue source.

👁️ What To Watch Next

Key upcoming developments include: (1) commercial launch performance of Zaynich in the U.S. and Indian markets; (2) regulatory outcome of the EMA review and any additional indications filed; (3) sales traction of the biotech insulin portfolio in emerging markets; and (4) quarterly earnings trends as launch costs taper off.